Pharma Two B to Present Additional Positive Results from P2B001 Phase 3 Trial at 2023 American Academy of Neurology Annual Meeting
April 23, 2023 08:30 ET
|
PHARMA TWO B LTD
Results showed P2B001, a once-daily fixed-dose combination of low dose pramipexole and low dose rasagiline, showed comparable efficacy to marketed optimally titrated pramipexole, with significantly...
Neuronascent Announces the Expansion of its Board of Directors
April 12, 2023 06:00 ET
|
Neuronascent, Inc.
ROCKVILLE, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a clinical-stage, neuron generating, biopharmaceutical company, is pleased to announce the addition of industry leader Emer...
Oncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell Cancer
February 06, 2023 08:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications,...
Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
January 30, 2023 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
January 10, 2023 10:15 ET
|
Silo Pharma, Inc.
Parkinson's disease, bipolar disorder, and chronic pain targeted in study Study aims to support psilocybin as a potential therapeutic for inflammatory disorders ENGLEWOOD CLIFFS,...
Zhittya Genesis Medicine announces: Free Zoom Webinar: Zhittya Parkinson’s Disease Research Study: 6-Month Patient Follow-Up Report
December 19, 2022 12:00 ET
|
Zhittya Genesis Medicine Inc
LAS VEGAS, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that they will be hosting a webinar on Tuesday, December 20, 2022, at 4:00 PM...
Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs
December 14, 2022 10:47 ET
|
Clinical Ink
Horsham, PA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Horsham, Pa.; December 14, 2022 — Clinical ink, a global life science technology company, has partnered with a leading biopharmaceutical organization...
Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results
November 21, 2022 09:00 ET
|
Oncotelic Therapeutics, Inc.
R&D cost reduced in excess of 95% while continuing expansion of our OT-101 clinical programs through our joint ventureG&A cost reduced by approximately 50%Net loss reduced by approximately...
With 13% of CAGR, Neurological Biomarker Market to Gain $14+ Billion Revenue by 2027 | Exclusive Report by The Insight Partners
November 14, 2022 06:58 ET
|
The Insight Partners
New York, Nov. 14, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners latest study on "Neurological Biomarker Market Size, Share, Growth, Trends and Forecast to 2027 – COVID-19 Impact and...
Parkinson's Disease Drug Market is Pegged to Reach $12.3 Billion By 2028 | Levodopa is the Most Popular Drug
November 07, 2022 09:21 ET
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford,USA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Parkinson's disease is a debilitating neurological disorder that affects millions of people worldwide. As the population ages, the number of people...